65,437 trials
Postoperative Pain
Primary: Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain — 9.4; 1.9; 1.2; 2.4 hours
Schizophrenia
Primary: Scale for the Asessment of Negative Symptoms (SANS) — 38.8; 53.7 Scores on a scale
Postoperative Pain
Primary: Number of Subjects With Breast Implant Rupture — 0; 0; 0; 0 participants
Normal Contact Lens Wearers
Primary: Corneal Staining — 184; 46.6; 77.8 units on a scale
Diabetic Peripheral Neuropathy
Primary: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12…
Inguinal Hernia
Primary: Time to First Use of Supplemental Pain Medication — 4.2; 13.75; 3.9; 5.2 hours
Growth Hormone Deficiency
Primary: Percentage of Dyads (Participant and Caregiver or Parent) and Adult Participants Reporting no Difference or Easier to Use for the New Genotropin Mark VII Injection Pen…
Newly Diagnosed Multiple Myeloma
Primary: Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC) — 136.1; 62.1; 56.1 weeks — p=<0.001
Smoking Cessation
Primary: Percentage of Participants With 7-day Point Prevalence From Week 3 to Less Than Week 7 — 59.55 Percentage of participants
Ankylosing Spondylitis
Primary: Number of Patients Using Healthcare Resources in the 48 Weeks Before and During Treatment — 6; 4; 8; 4 patients — p=0.743
Antithrombin III Deficiency
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Venous Thrombosis (DVT) — 0 Participants
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) at Steady-State (After 3rd Dose) — 193.33; 165.70 mcg/mL
Breast Cancer · Breast Neoplasms
Primary: Objective Response (Complete Clinical Response+ Partial Response) — 20 percentage of patients
Cerebrovascular Accident · Hemiplegia
Primary: Box and Block Test; Data Collected = Number of Blocks Moved — 24.5; 24.6; 40; 27.5 Blocks — p=<0.05
Metabolic Syndrome · Hypertension
Primary: Change in MAP During Placebo — -0.9; 2.7; -7.9 mmHg